Skip to search formSkip to main contentSkip to account menu

advexin

Known as: INGN 201, INGN-201, RPR/INGN-201 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Ad5CMV-p53 geneViral Vaccines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Preclinical Evaluation of Differentially Targeting Dual Virotherapy for Human Solid Cancer
Multimodal approaches combining drugs that differentially function is the most popular regimen for treating human cancer… 
Review
2008
Review
2008
Gene therapy: the first approved gene-based medicines, molecular mechanisms and clinical indications.
As gene therapy has matured from clinical trials to the first commercial products, understanding of the mechanisms of gene… 
2008
2008
Ark floats gene therapy's boat, for now
Review
2007
Review
2007
INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Introgen and its wholly owned European subsidiary Gendux AB are developing an adenoviral p53 gene therapy as a treatment for… 
2006
2006
Controversial Chinese gene-therapy drug entering unfamiliar territory
Experience in clinic is raising issues that Western researchers will not have seen before 
2006
2006
Gene therapy finds welcoming environment in China
China in November became the first country to have approved two drugs based on gene therapy. The approvals have fueled quick… 
2006
2006
Abnormal overexpression of p53 is a predictive molecular biomarker of Advexin (adenoviral p53) efficacy in recurrent squamous cell carcinoma of the head and neck (SCCHN)
B52 The p53 signaling pathway integrates diverse environmental stimuli and serves as the nodal point for regulation of cell… 
Highly Cited
2004
Highly Cited
2004
Evidence That Transfer of Functional p53 Protein Results in Increased Apoptosis in Prostate Cancer
Purpose: INGN 201 (Ad-p53) is a replication-defective adenoviral vector that encodes a wild-type p53 gene driven by the… 
Review
2003
Review
2003
INGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy--Introgen, RPR/INGN 201.
Introgen's adenoviral p53 gene therapy [INGN 201, ADVEXIN] is in clinical development for the treatment of various cancers. The… 
Review
2001
Review
2001
INGN-201. Introgen Therapeutics.
In April 2001, Aventis and Introgen signed a letter of intent to restructure their collaboration arrangement, giving Introgen… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)